Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC labeling

This article was originally published in The Tan Sheet

Executive Summary

SmithKline Beecham tells FDA that OTC manufacturers should be allowed to start a heading or subheading on one column of a "Drug Facts" box and continue onto the next column by repeating the heading or subheading and adding "continued" in parentheses. In a Jan. 28 letter discussing FDA's draft guidance on the use of a column format for required "Drug Facts" information, SmithKline says its suggestion would replace the need for the "Drug Facts (continued)" statement at the top of subsequent columns, "but still indicate the flow of the text to the consumer." CHPA and CTFA also have commented on the FDA guidance (1"The Tan Sheet" Feb. 14, p. 8)

You may also be interested in...



OTC "Drug Facts" Column Size Flexibility Sought By Industry

The use of different size columns for multiple "Drug Facts" boxes on OTC labels would give manufacturers greater flexibility to include graphics within the box, industry trade groups tell FDA.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel